TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00470080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venepuncture
Description: venepuncture
Study: NCT03038646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101
Study: NCT04299100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Program for Participants with No/Mild Sleep Apnea
Description: Participants randomized to the Sleep Health Program will receive the Self-Management for Sleep Care videos and digital materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Program for Participants with Moderate/Severe Sleep Apnea
Description: Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea will receive the Self-Management for Sleep Care videos and digital materials, and be recommended for referral to a sleep clinic as part of standard of care.
Study: NCT04926935

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological analysis of blood samples.
Description: Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
Study: NCT00559273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: 1.2 mcg/kg SC monthly, starting dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: 0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
Study: NCT02603744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraovarian injection of Adipose derived Stromal cells (ADSCs)
Description: Intra-ovarian injection of Adipose derived mesenchymal stem cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraovarian injection of Adipose derived Stromal cells (ADSCs)
Description: Intra-ovarian injection of Adipose derived mesenchymal stem cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraovarian injection of Adipose derived Stromal cells (ADSCs)
Description: Intra-ovarian injection of Adipose derived mesenchymal stem cells.
Study: NCT03387787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoTab
Description: The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: During the study, patients will be treated with basal Insulin degludec
Study: NCT02917460

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic sequencing and molecular diagnostic results, if any
Description: Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
Study: NCT04619394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic exercise - own monitors program
Description: Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic exercise - AIPAP program
Description: Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes.
Study: NCT00536172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants take 10 mg for 1 week and then 20 mg for 15 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo distribution matches the active medication.
Study: NCT02276859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
Study: NCT01858233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Modification
Description: Intensive dietary counseling, increased physical activity, lactation counseling
Study: NCT01424735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycobacterium w.(Mw)-freeze dried extract 0.5ml
Description: 0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
Study: NCT03966326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane and fentanil
Description: Patients will receive standard general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane and fentanil plus PECS II block
Description: Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
Study: NCT02455401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose remifentanil
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose remifentanil
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No remifentanil
Description: Intervention: no remifentanil will be administrated
Study: NCT00505947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: infliximab 5 mg/Kg body weight by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: infliximab
Description: infliximab 5 mg/Kg body weight by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo 5 mg/Kg body weight by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 5 mg/Kg body weight by intravenous infusion
Study: NCT00687791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
Description: Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
Study: NCT02104960

Intervention type: OTHER
Intervention: Dermatological clinical examination
Description: Clinical pictures, Dermatoscopy, Elastography, Sebumetry

Intervention type: OTHER
Intervention: Biopsy
Description: Skin biopsy for examinations by confocal microscopy ex vivo and histopathology

Intervention type: OTHER
Intervention: Confocal microscopy in vivo
Description: Examination by confocal microscopy in vivo
Study: NCT00998556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
Study: NCT00156936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral naltrexone to Medisorb naltrexone 380 mg
Description: Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
Study: NCT04070911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WATER
Description: ORAL WATER
Study: NCT03608215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
Study: NCT00422747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasondipropionate
Description: 2 x 100 ug dd for two months, via aerochamber
Study: NCT03593980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: 400ml cranberry juice
Study: NCT00172055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT04070911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICE APPLICATION
Description: ICE APPLICATION
Study: NCT03063814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP
Description: See arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PHY
Description: see arm description
Study: NCT05240495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive-behavioural therapy
Description: Internet-based Cognitive-behavioural therapy protocol was based on contemporary CBT techniques adapted for adjustment disorders, and recovery from work training inspired by Hahn et al. \[50\]. The iCBT program consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive-behavioural therapy
Description: Internet-based Cognitive-behavioural therapy protocol was based on contemporary CBT techniques adapted for adjustment disorders, and recovery from work training inspired by Hahn et al. \[50\]. The iCBT program consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work-focused Cognitive-behavioural therapy
Description: The Work-focused Cognitive-behavioural therapy consisted of the exact generic iCBT-modules included in the first experimental group and of additional work-focused modules adapted for adjustment disorders. The W-iCBT added about 2-3 regular pages compared to the generic iCBT.
Study: NCT00202982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 20 mg
Description: glatiramer acetate 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 40 mg
Description: glatiramer acetate 40 mg
Study: NCT02351466

Intervention type: OTHER
Intervention: Observational
Study: NCT03625440

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: The Digit span test and PASAT with waterpipe smoking
Description: Cognitive tests at baseline and 30minutes after waterpipe smoking

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: The Digit span test and PASAT without waterpipe smoking
Description: The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
Study: NCT03643328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasal swabs
Description: Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
Study: NCT03933956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Oral empagliflozin 10mg daily for 30 days
Study: NCT01285037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2801653
Description: LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
Study: NCT04325100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switch - Individual sessions
Description: Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switch - Group programme
Description: Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French).
Study: NCT01388270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a pre-heparin-coated hemodialysis filter; Hepran
Description: Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
Study: NCT03581422

Intervention type: DRUG
Intervention: hCG administration before embryo transfer
Description: Thawed embryo transfer with ovulation triggered by hCG
Study: NCT02770625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302
Description: 60 U/kg given intravenously
Study: NCT03027830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFR pressure-wire
Description: The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Other diagnostic devices (including FFR and angiography)
Study: NCT01529060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylbutyrate
Description: Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
Study: NCT01450462

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
Study: NCT01804738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jasmine rice
Description: Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
Study: NCT01987908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04058587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Study: NCT00189462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01262625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCTA
Description: Complete diagnostic CCTA per protocol specifications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPECT MPI/ICA
Description: Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
Study: NCT04075331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 100mg subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for subcutaneous injection
Study: NCT03089957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: 200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care in ICU.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care in ICU.